A Revolutionary Approach to Diagnostic Testing for Resource-limited Settings
Universal Access for a Healthier Future for All
Imagine a world where universal access to quality diagnostic testing and viral-load monitoring for the most prevalent viral diseases are available everywhere, for everyone. The vision is simple, but translating it into tangible results can be challenging in resource-limited settings. As a leading provider of medical diagnostics, Hologic is working towards making this a reality.
Simple
Scalable
Sustainable
The Global Access Initiative is our solution to promote simple, scalable and sustainable access to cost-effective and quality diagnostic testing for countries that need it most.
Video Resources
What’s in the way of Africawide molecular diagnostic roll out?
How are molecular diagnostics expanding access to diagnostic testing for viral diseases in low resource settings? Devex investigates.
Together we can improve care where it is needed most.
The Hologic Global Access Initiative is a partnership with the Clinton Health Access Initiative, Inc. (CHAI) and MedAccess (backed by the UK government) to mitigate the burden of viral diseases in areas with high prevalence by providing greater access to testing using the Panther® system. Together with these organizations, we deliver an all-inclusive* pricing structure that allows eligible countries to procure testing. The test result price is inclusive of all necessary reagents & consumables, instrument placement, service & maintenance, freight & logistics, and replacement tests.†
Highly Sensitive Viral Assays to Meet the UNAIDS Goals
Hologic supports the 2030 UNAIDS 95-95-95 treatment target to help end the AIDS epidemic through HIV detection and antiretroviral therapy, with the end goal of viral suppression for persons living with HIV/AIDS. The Global Access Initiative continues this support and expands this reach to include other common viral targets.
Eligible tests include‡:
- Aptima® HIV-1 Quant Dx assay – Aids in the diagnosis, confirmation and clinical management of HIV-1 infection. Now WHO prequalified.
- Aptima® HCV Quant Dx assay – Aids in the diagnosis, confirmation and clinical management of HCV infection.
- Aptima® HBV Quant assay – Aids in the clinical management of HBV infection.
- Aptima® HPV assay – Detects 14 high-risk HPV types
- Aptima® SARS-CoV-2 assay – Detects SARS-CoV-2 infection
An accessible pathway for healthcare in resource-limited settings.
This program creates an accessible pathway for healthcare in resource-limited settings, where financial and operational challenges can create barriers to care. It was designed to help countries overcome these barriers so their citizens can access crucial testing.
